VYONDYS, VYONDYS 53, the VYONDYS 53 Logo, AMONDYS, AMONDYS 45, and the AMONDYS 45 Logo. accelerated approval status and/or FDA package insert
Vyondys 53 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; February 2024. FDA grants accelerated approval to first targeted
Casimersen (Amondys 45) View full drug information. Casimersen is Vyondys 53 (golodirsen) [package insert]. Cambridge, MA: Sarepta
5. Patient will not use golodirsen (Vyondys 53 ) together with Viltolarsen [Viltepso ]) Renewal Approval: 6 months References: 1. Vyondys 53 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; March 2024. 2. Viltepso [package insert]. NS Pharma, Inc. Paramus, NJ 3. Clinical Pharmacology [database online].
Vyondys 53 (golodirsen) is an antisense oligonucleotide indicated for the Vyondys 53 (golodirsen) [package insert]. Cambridge, MA: Sarepta
) Vyondys 53 Package Insert (Sarepta Therapeutics) – Revised 12/2024. 2.) Lexicomp monograph for Vyondys 53 – reviewed . 3.) Drug
Vyondys 53 while maintaining optimal therapeutic outcomes. References. 1. Vyondys 53 [package insert]. Cambridge, MA: Sarepta Therapeutics
AMONDYS 45 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; 2024. 3. VILTEPSO [package insert]. Paramus, NJ: NS Pharma, Inc.; 2024. 4. VYONDYS
Individual is using another exon skipping agent for DMD (including but not limited to Exondys 51, Vyondys 53); OR, Amondys 45 [package insert]
I would like to know more about this package. ^.^